VYBIO

Vybio focuses on the research and development of new drugs for oncology and hepatitis B. The core members of the team have 30 years of experience in tumor and hepatitis B drug research and development, and come from well-known pharmaceutical companies such as WuXi AppTec, Pfizer, BMS, etc., using a specific tumor microenvironment to independently innovate prodrug design and screening, and developed a series of global drugs. Preclinical research on precisely targeted small molecule anticancer prodrug compounds protected by intellectual property rights is being carried out in an orderly manner.